Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal. Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally...
You must be a Standard 1 Year member to access this content.
